Guidelines     MGP Ltd



Forthcoming guidance
 
Published guidance
 
Select guidance type:
Select Clinical speciality:

Date: from to

Search



Title Type Clinical speciality   Expected date   Last updated date
Clostridioides difficile infection: antimicrobial prescribing NICE Clinical Guideline Infection Jul 2021 -
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) NICE Clinical Guideline Infection Jul 2021 Jul 2021
Bronchiolitis in children NICE Clinical Guideline Respiratory Aug 2021 Jul 2021
olaparib (Lynparza) SMC advice Cancer Aug 2021 Jul 2021
patiromer sorbitex calcium (Veltassa) SMC advice Haematological conditions Aug 2021 -
avatrombopag (Doptelet) SMC advice Haematological conditions Aug 2021 -
autologous anti-CD19-transduced CD3+ cells (KTE-X19) (Tecartus) SMC advice Cancer Aug 2021 -
nivolumab (Opdivo) SMC advice Cancer Aug 2021 Jul 2021
avelumab (Bavencio) SMC advice Cancer Aug 2021 -
inclisiran (Leqvio) SMC advice Haematological conditions Aug 2021 Jul 2021
guselkumab (Tremfya) SMC advice Musculoskeletal and joints Aug 2021 -
Antimicrobial prescribing: delafloxacin for community acquired pneumonia NICE Evidence summary Infection Aug 2021 Jul 2021
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management NICE Clinical Guideline Neurology Aug 2021 Apr 2021
Sapropterin for treating phenylketonuria NICE Technology Appraisal Genetic conditions Aug 2021 Apr 2021
Melatonin for treating insomnia in adults with visual disorders NICE Evidence summary Neurology Aug 2021 Jul 2021
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation NICE Technology Appraisal Cancer Aug 2021 -
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma NICE Technology Appraisal Cancer Aug 2021 Feb 2021
Antenatal care NICE Clinical Guideline Women's health Aug 2021 Jul 2021
Venous thromboembolism in adults (QS update) NICE Quality Standard Cardiovascular Aug 2021 Jul 2021
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s NICE Clinical Guideline Respiratory Aug 2021 Jul 2021
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) NICE Technology Appraisal Cancer Aug 2021 Jul 2021
Babies, children and young people's experience of healthcare NICE Clinical Guideline Paediatrics Aug 2021 Mar 2021
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy NICE Technology Appraisal Cancer Aug 2021 Jul 2021
Chronic kidney disease: assessment and management (update) NICE Clinical Guideline Renal conditions Aug 2021 Jul 2021
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma NICE Technology Appraisal Cancer Aug 2021 -
Berotralstat for preventing acute attacks of hereditary angioedema NICE Technology Appraisal Genetic conditions Aug 2021 -
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations NICE Technology Appraisal Cancer Aug 2021 -
End of life care (QS update) NICE Quality Standard Public health Sep 2021 Jul 2021
Workplace health: long-term sickness absence and capability to work NICE Quality Standard Public health Sep 2021 Jul 2021
amikacin (Arikayce) SMC advice Respiratory Sep 2021 Jul 2021
selpercatinib (Retsevmo) SMC advice Cancer Sep 2021 -
pembrolizumab (Keytruda) SMC advice Cancer Sep 2021 -
filgotinib (Jyseleca) SMC advice Musculoskeletal and joints Sep 2021 -
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia NICE Technology Appraisal Haematological conditions Sep 2021 Jul 2021
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy NICE Technology Appraisal Cancer Sep 2021 Jul 2021
Crizanlizumab for preventing sickle cell crises in sickle cell disease NICE Technology Appraisal Haematological conditions Sep 2021 Jul 2021
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection NICE Technology Appraisal Cancer Sep 2021 -
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma NICE Technology Appraisal Cancer Sep 2021 Jul 2021
Crizanlizumab for preventing sickle cell crises in sickle cell disease NICE Technology Appraisal Genetic conditions Sep 2021 -
Bimekizumab for treating moderate to severe chronic plaque psoriasis NICE Technology Appraisal Skin and wound care Sep 2021 -